BioNTech reports first pumitamig data in second-line lung cancer

BioNTech and Bristol Myers Squibb said on Oct. 25 that single-arm Phase 2 ROSETTA Lung-107 showed a 36.7 percent confirmed response rate in 30 evaluable patients given pumitamig plus docetaxel after immunotherapy and chemotherapy. In all 50 treated patients, median progression-free survival was 6.9 months at a July 10 cutoff, and the upper bound of the confidence interval was not reached. The companies reported no pumitamig-related deaths. The study has no randomized control arm.